We have evaluated a recently introduced colour test kit for the determination of serum angiotensin I-converting enzyme catalytic activity. p-Hydroxyhippuric acid, liberated from p-hydroxyhippuryl-L-histidyl-L-leucine by angiotensin I-converting enzyme, is cpnverted into a quinoneimine dye with an absorption maximum at 505 nm. The procedure shows excellent linearity over the whole ränge of catalytic activities found in serum. Intra-and inter-assay coefficients of Variation are 2-5 and 7-10% respectively. Correlation with a modified Cushman-Cheung ((1971) Biochem. Pharmacol. 20, 1637-1648) method currently used in our laboratory is good, with r = 0.985 and a regression equation of y (colour kit) = 0.423 (CushmanCheung) + 0.765. Haemoglobin, lipids, bilirubin and prednisone do not interfere but uric acid in concentrations higher than 600 / does. No extraction step is required. The assay is very rapid, and more than twenty samples can be determined in an hour. 
Introduction
Determination of the serum catalytic activity of angiotensin I-converting enzyme (EC 3.4.15.1) is increasingly being used äs a vatuable tool in the diagnosis and inanagement of sarcoidosis (1) (2) (3) (4) and certain other diseases such äs silicosis (5) , asbestosis (5), Gaucher's disease (6) and, possibly, malignant histiocytosis (7, 8) . Serum angiotensin I-converting enzyme is elevated in the active stages of these diseases, äs it is in hyperthyroidism (9) , in chronic liver disease (10) , and in diabetes mellitus with severe retinopathy (l 1). In contrast, serum angiotensin I-converting enzyme is depressed in patients with malignant lymphomas (12) , leukaemia (12) , multiple myeloma (12) and lung cancer (13) .
Many methods for determining angiotensin I-converting enzyme have been described in the literature, most of them based on the enzymatic cleavage of the tripeptide Substrates hippuryl-L-histidyl-L-leucine or hippuryl-glycyl-glycine. Quantitation of one of the cleavage products, hippuric acid or the dipeptide, has been achieved in a wide variety of ways: spectrophotometric (14, 15) , fluorimetric (16, 17) , radioisotopic (18) , colorimetric (19) (20) (21) , or by HPLC (21) (22) (23) . In most assays, a time-consuming extraction procedure is required. Recently, a diagnostic kit has been introduced by the Fujizoki Pharmaceutical Co, Tokyo, Japan, based on the colorimetric assay reported by Kasahara & Ashihara (19) . In this method, p-hydroxyhippuric acid is cleaved by angiotensin I-converting enzyme from the Substrate p-hydroxyhippuryl-L-histidyl-L-leucine and converted into p-hydroxybenzoic acid by the enzyme hippuricase. Reaction with sodium periodate and 4-aminoantipyrine then yields a quinoneimine dye with an absorption maxitnum at 505 nm. No extraction Step is necessary, and the absorbance can be read within minutes of stopping the incubation.
We have evaluated the performance of this angiotensin I-converting enzyme colour kit and compared it with the modified Cushman-Cheung method (15) , which has been used in this laboratory for the last few years.
Materials and Methods

Test kit, chemicals
Angiotensin I-converting enzyme colour kits (Fujizoki Pharmaceutical Co, Tokyo, Japan) were a gif t from Gist-Brpcades Pharmaca Nederland BV, Rijswijk, The Netherlands. One package contained four reagents: 1) l vial with 24 ml of buffer solution (0.12 mol/1 boric acid, 0.7 mol/1 sodium Chloride, pH 8.3);
2) 2 vials of lyophilized Substrate, which, after reconstitution with 11 ml of buffer solution each, contained 10 mmol/1 p-hydroxyhippuryl-L-histidyl-L-leucine, 2.5 mmol/1 4-aminoantipyrine and 3 kU/1 hippuricase;
3) 2 vials of stopper solution (31 ml each) containing 3 mmol/1 disodium ethylenediaminetetraacetate and 2 g/l Triton X-100; and 4) 2 vials of lyophilized developer, each containing 6.5 mmol/1 sodium periodate after reconstitution with 31 ml of stopper solution.
Hippuryl-L-histidyl-L-leucine was obtained frorn Sigma, St. Louis, USA.
Procedures
In the procedure recommended by the manufacturer, 0.5 ml of the Substrate solution is added to 0.1 ml of sample serum in a test tube. The tube is mixed and incubated at 37 °C for 20 minutes.
Then l .5 ml of the stopper/developer solution is added, and after mixing and incubating at 37 °C fof 3 minutes, the absorbance is read at 505 nm against distilled water. Blanks are prepared by adding the sample serum aftef the 20 minutes incubation Step.
We have modified this procedure in three ways: 1) By halving the amounts of serum and reagents used and ernploying semimicrocuvettes, twice s many samples can be assayed with one paclcage.
2) The method of preparing blanks by adding serum after the ineubation step is rather inconvenient. We prepared blanks by pipetting serum in all test tubes at the same time, and by adding 10 μΐ of a disodium ethylenediaminetetraacetate solution (104 mg in 10 ml of 0.15 mol/1 NaCl, brought to pH 8.3 with l mol/1 NaOH) to the tubes for the blanks. For 17 samples, blanks were prepared according to the manufacturer and by our own method. Blank absorbance (mean ± SEM) was 0.061 ± 0.015 and 0.067 ± 0.022 respectively, while calculated angiotensin I-converting enzyme catalytic activity (mean ± SD) was 32.1 ± 22.8 vs. 31.6 ± 22.4 μΓηοΙ/min · l of p-hydroxyhippuric acid liberated.
3) To allow for the processing of a larger number of samples in the same batch, we lengthened the incubation time to 30 nxiii tes, with the added ad van tage of a higher sample absorbance.
For the evaluation of the kit we thus used the following procedure: serum (50 μΐ) was pipetted into the test tubes; to the tubes for the blanks were added 10 μΐ of a disodium ethylenediaminetetraacetate solution (final concentration iri the incubation mixture l mmol/1). Substrate solution (250 μΐ) was added, and the tubes were mixed and incubated at 37 °C for 30 minutes. After adding 750 μΐ of the stopper/developer solution, followed by mixing and incubating for 3 minutes at 37 °C, the absorbance was read at 505 nm. Samples were measured in duplicate. 
Results
Linearity
Three sera were incubated for various time intervals s indicated in figure 1 . Formation of p-hydroxyhippuric acid was found to be linear up to 130 nmol, corresponding to a conversion of 5.2% of the substrate. With an incubation time of 30 min and a sample portion of 50 μΐ, the ssay w ld thus be linear up to an angiotensin I-converting enzyme catalytic activity of 85 U/l. This was borne out in an experiment in which three sera with increasing angiotensin I-converting enzyme catalytic activity were assayed undiluted and in various dilutions with 0.15 mol/1 NaCl ( fig. 2) . Linearity was excellent, even for the serum with the highest catalytic activity (84.6 U/l, the highest we have ever encoiirjtered). 
Precision
Sera with l w, medium and high angiotensin I-converting enzyme catalytic activity were used for determining both within-run and between-run variability. Reproducibility was good, s can be seen in table 1. In a series of 80 duplicate measurements (mean angiotensin I-converting enzyme 29.7 U/l) the Standard deviation of the differences between duplicates was 2.0 U/l. In our opinion it is thus not necessary to measure samples in duplicate. We recommend that sera are briefly centrifuged before use, s pipetting of turbid sera is probably one of the main causes of measurement errors. 
Comparison with the modified Cushman-Cheung method
Interference
Haemolytic sera, lipaemic sera, and sera with a high bilirubin content were investigated and found not to interfere in the determination of angiotensin I-converting enzyme: results fitted the regression line with the Cushman-Cheung method, and straight lines were obtained when the samples were assayed after dilution with 0.15 mol/1 NaCl. Blank absorbances were higher than with normal sera (0.1-0.3). Uric acid does interfere; when the uric acid concentration of three normal sera (<0.6 mmol/1) was increased by 0.6, 1.5, 3.0 and 6.0 mmol/1, the measured catalytic activity decreased by 5,12,15 and 21% respectively, compared with fhe non-enriched sera.
Addition of various amounts of prednisone, up to 1.4 mmol/1, did not change the measured angiotensin I-converting enzyme value of serum.
Measurement of unblocked and total angiotensin lconverting enzyme catalytic activity after captopril
Angiotensin I-converting enzyme can be blocked by the converting enzyme Inhibitor captopril (Capoten®), a new antihypertensive drug. We have previously reported that the angiotejqsin I-converting enzyme Inhibition can be rapidly feversed in vitro by the addition of Nrethylmaleimide to the incubation mixture for the Cushman-Cheung method (final concentration 0.1 mmol/1), th s allowing the measurement of total, i.e. blocked and unblocked angiotensin I-converting enzyme catalytic activity (15) . To see whether the same holds for the colour kit, we added captopril (5 μg) to 1.5 ml f four sera. Angiotensin I-converting enzyme catalytic activity was then determined in this plasma, and also after the addition of various amounts of N-ethylmaleimide to the incubation mixture. Results are shown in figure  4 . 
Colour stability
The angiotensin I-converting enzyme catalytic activity of seven sera was calculated from the absorbance measured immediately after the 3-min incubation step with the stopper/developer solution, and subsequently from the absorbance measured after various times at room temperature or at 4 °C. Results, expressed s the fraction of the activity calculated from the immediately measured absorbance, are shown in table 2. 
Discussion
In contrast to the Cushman-Cheung method, the colour kit shows excellent linearity over the whole ränge of angiotensin I-converting enzyme catalytic activities likely to be encountered in serum. This difference can, at least partly, be attributed to the lower Vmax of the reaction of angiotensin I-converting enzyme with p-hydroxyhippuryl-L-histidyl-L-leucine äs compared with hippuryl-L-histidyl-L-leucine (19) , resulting in a lower rate of hydrolysis with the colour kit than with methods employing hippuryl-Lhistidyl-L-leucine. It is of interest to note the difference in Chloride dependency. With hippuryl-L-histidyl-L-leucine, the optimal Chloride concentration in the incubation mixture is 0.3 mol/1 (14) , whereas in the colour kit, using p-hydroxyhippuryl-L-histidyl-L-leucine äs a Substrate, the optimal concentration of Chloride is 0.58 mol/1 (25) .
The lower rate of hydrolysis makes the colour kit less sensitive than some other methods described in the literature, but this is hardly a disadvantage, since the sensitivity is adequate for measuring angiotensin Iconverting enzyme in serum. The sensitivity might become a limiting factor only when precise measurements are needed in fluids other than serum, with much lower angiotensin I-converting enzyme catalytic activity, or in sera containing converting enzyme inhibitors. In these cases, however, the sensitivity of the colour kit can be enhanced by modifying the procedure, e.g. by a longer incubation time or by using a larger volume of the sample.
The precision of the assay is good. Both serum and heparinized plasma can be used, äs in the CushmanCheung method. Only uric acid in abnormally high concentrations was found to interfere.
The method for measuring total angiotensin I-converting enzyme catalytic activity in sera of patients treated with captopril is not fully applicable when using the colour kit. Nearly 0.90 of the total activity is measured, however, when N-ethylmaleimide is present in the incubation mixture in a concentration of 0.25 mmol/1. This is adequate if one just wants to check 'patient compliance'.
In conclusion, we find the colour kit to be a simple, reliable and rapid method for determining serum angiotensin I-converting enzyme catalytic activity. Twenty or more samples can be measured in an hour. No extraction procedure is necessary, and only a simple spectrophotometer is required.
